Oruka Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '25 Dec 31, 2025	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-105.43	-5.34	-9.93	-19.32	-9.74
Depreciation & Amortization	0.08	0.02	0.02	0.02	0.01
Stock-Based Compensation	24.24	0.69	0.56	0.5	0.04
Other Adjustments	-4.55	0.1	0.1	0.08	0.09
Changes in Accounts Payable	0.69	0.03	-0.78	-0.41	1.1
Changes in Accrued Expenses	7.25	-0.6	-1.69	0.55	1.14
Changes in Other Operating Activities	-10.49	0.1	0.81	-0.16	-0.36
Operating Cash Flow	-88.21	-5.01	-10.91	-18.76	-7.73
Capital Expenditures	-0.21	-	-0	-0.04	-0.02
Purchases of Investments	-520.96	-	-	-	-
Proceeds from Sale of Investments	424.42	-	-	-	-
Investing Cash Flow	-96.75	-	-0	-0.04	-0.02
Issuance of Common Stock	170.32	-	-	24.07	50.89
Net Common Stock Issued (Repurchased)	170.32	-	-	24.07	50.89
Other Financing Activities	-	-	-	-0.98	-2.44
Financing Cash Flow	170.32	-	-	23.09	48.45
Net Cash Flow	-14.64	-5.01	-10.91	4.29	40.71
Free Cash Flow	-88.42	-5.01	-10.91	-18.81	-7.74
Free Cash Flow Per Share	-1.94	-4.17	-9.09	-16.23	-19.73
Levered Free Cash Flow	-108.11	-5.8	-11.57	-19.38	-7.87
Unlevered Free Cash Flow	-124.73	-7.75	-12.24	-19.39	-7.89

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q